Aptinyx to Present Preclinical Data on NYX-458 at the AD/PD 14th International Conference on Alzheimer’s & Parkinson’s Di...
March 22 2019 - 7:27AM
Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical
company developing transformative therapies for the treatment of
brain and nervous system disorders, today announced upcoming
presentations highlighting preclinical data on its novel NMDA
receptor modulator, NYX-458, at the AD/PD 14th International
Conference on Alzheimer’s & Parkinson’s Diseases in Lisbon,
Portugal.
“We are excited to present these data, demonstrating the
striking effects that NYX-458 has on cognitive impairment in a
highly translatable non-human primate model of Parkinson’s
disease,” said Cassia Cearley, Ph.D., vice president of research at
Aptinyx. “Across the cognitive assessments used in the study,
NYX-458 demonstrated rapid, robust, and enduring reversal of
cognitive impairment. On some measures, cognitive performance was
restored to healthy baseline levels. We are highly encouraged by
these data and are working to advance NYX-458 in clinical
development and toward patients that need better therapeutic
options.”
Oral Presentation Details:
Presentation Title: The NMDAr modulator NYX-458
results in long-lasting improvement in several cognitive domains in
a primate model of Parkinson’s disease cognitive
impairmentPresenter: Cassia Cearley, Ph.D.,
AptinyxTime and Location: Friday, March 29th,
9:15am GMT, Auditorium V
Poster Presentation Details:
Presentation Title: The NMDAr modulator NYX-458
results in long-lasting improvement in several cognitive domains in
a primate model of Parkinson’s disease cognitive impairment (Poster
Number: 522)Presenter: Cassia Cearley, Ph.D.,
AptinyxPoster Presentation: March 29th and March
30th
Presentation Title: The NMDAr modulator NYX-458
does not worsen motor symptoms or interfere with L-Dopa’s
anti-parkinsonian effect in a non-human primate Parkinson’s disease
model. (Poster Number: 521)Presenter: Cassia
Cearley, Ph.D., AptinyxPoster Presentation: March
29th and March 30th
About NYX-458NYX-458 is a novel, oral NMDA
receptor modulator currently in Phase 1 clinical development for
the treatment of cognitive impairment associated with Parkinson’s
disease. In preclinical studies in rodents and non-human primates,
NYX-458 has demonstrated rapid, robust, and enduring effects on
cognitive impairment. A Phase 1 study evaluating the safety,
tolerability, pharmacokinetics, and CNS exposure of NYX-458 is
ongoing, and Aptinyx expects to report data from the study in the
first half of 2019.
About AptinyxAptinyx Inc. is a clinical-stage
biopharmaceutical company focused on the discovery, development,
and commercialization of proprietary synthetic small molecules for
the treatment of brain and nervous system disorders. Aptinyx has a
platform for discovery of novel compounds that work through a
unique mechanism to modulate – rather than block or over-activate –
NMDA receptors and enhance synaptic plasticity, the foundation of
neural cell communication. The company has three product candidates
in clinical development in central nervous system indications,
including chronic pain, post-traumatic stress disorder, and
cognitive impairment associated with Parkinson’s disease. Aptinyx
is also advancing additional compounds from its proprietary
discovery platform, which continues to generate a rich and diverse
pipeline of small-molecule NMDA receptor modulators with the
potential to treat an array of neurologic disorders. For more
information, visit www.aptinyx.com.
Forward-Looking StatementsStatements contained
in this press release regarding matters that are not historical
facts are “forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995. Because such
statements are subject to risks and uncertainties, actual results
may differ materially from those expressed or implied by such
forward-looking statements. Such statements include, but are not
limited to, statements regarding the company’s business plans and
objectives, therapeutic effects of the company’s product
candidates, expectations regarding the design, implementation,
timing, and success of its current and planned clinical trials,
expectations regarding its preclinical development activities, and
expectations regarding its uses and sufficiency of capital. Risks
that contribute to the uncertain nature of the forward-looking
statements include: the success, cost, and timing of the company’s
product candidate development activities and planned clinical
studies; the company’s ability to execute on its strategy;
regulatory developments in the United States and foreign countries;
as well as those risks and uncertainties set forth in the company’s
most recent annual report on Form 10-K and in its other filings and
reports with the United States Securities and Exchange Commission.
All forward-looking statements contained in this press release
speak only as of the date on which they were made. Aptinyx
undertakes no obligation to update such statements to reflect
events that occur or circumstances that exist after the date on
which they were made.
Investor Contacts:Nick SmithAptinyx
Inc.ir@aptinyx.com847-871-0377
Rachel FrankStern Investor
Relationsrachelf@sternir.com212-362-1200
Media Contact:Jordann PhillipsCanale
Communicationsjordann@canalecomm.com619-849-6009
Source: Aptinyx Inc.
Aptinyx (NASDAQ:APTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aptinyx (NASDAQ:APTX)
Historical Stock Chart
From Apr 2023 to Apr 2024